Although clinical trials in cancer patients had indicated that the combination of HSP90 inhibitors with other drugs display acceptable toxicity levels [16, 17], our results showed that 17-AAG caused a remarkable reduction on PASMCs growth in normal condition, and the PCNA expression was decreased by 17-AAG in a control setting. The gene discussed is PCNA; the disease is cancer.